Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus Cadila gets...

    Zydus Cadila gets USFDA nod to Lurasidone Hydrochloride Tablets

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-22T16:59:56+05:30  |  Updated On 22 March 2019 4:59 PM IST
    Zydus Cadila gets USFDA nod to Lurasidone Hydrochloride Tablets

    Zydus Cadila has got final approval from the US Food and Drug Administration (USFDA) to market Lurasidone Hydrochloride Tablets USP in the strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg.


    Ahmedabad: City-based Drugmaker, Zydus Cadila has received the final approval from the US health regulator to market Lurasidone Hydrochloride Tablets USP (US RLD – Latuda Tablets).


    The company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg.


    The product will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.


    The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder. It may also help to decrease hallucinations (hearing/seeing things that are not there).


    Also Read: Zydus Cadila gets USFDA nod to antiviral ointment Acyclovir


    The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.


    Zydus Cadila is a global pharmaceutical firm which discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide.


    Also Read: Zydus Cadila gets USFDA nod for Valsartan, Hydrochlorothiazide tablets to treat high BP

    Cadila Healthcarecertain mental/mood disordersCompanies based in AhmedabadhealthHealthcareHeterocyclic compoundsLactamsLurasidonemanufacturing facilityMental disorderOrganic compoundspharmapharma newspharma news indiaPharmaceutical industryPiperazinesUSFDAzydusZydus Cadila

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok